Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021
Глобальное, региональное и национальное бремя диабета с 1990 по 2021 год и прогнозы распространённости до 2050 года: систематический анализ для исследования глобального бремени болезней 2021 года
2023-06-23
SCID: 54.1/egd3bm42
Discuss with AI
DisMod-MR 2.1Global Burden of Disease Studydiabetes prevalencediabetes prevalence projectionsdisability-adjusted life-years
Figures from the paper
Abstract (AI)
BACKGROUND: Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. Using the most recent evidentiary and analytical framework from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), we produced location-specific, age-specific, and sex-specific estimates of diabetes prevalence and burden from 1990 to 2021, the proportion of type 1 and type 2 diabetes in 2021, the proportion of the type 2 diabetes burden attributable to selected risk factors, and projections of diabetes prevalence through 2050. METHODS: Estimates of diabetes prevalence and burden were computed in 204 countries and territories, across 25 age groups, for males and females separately and combined; these estimates comprised lost years of healthy life, measured in disability-adjusted life-years (DALYs; defined as the sum of years of life lost [YLLs] and years lived with disability [YLDs]). We used the Cause of Death Ensemble model (CODEm) approach to estimate deaths due to diabetes, incorporating 25 666 location-years of data from vital registration and verbal autopsy reports in separate total (including both type 1 and type 2 diabetes) and type-specific models. Other forms of diabetes, including gestational and monogenic diabetes, were not explicitly modelled. Total and type 1 diabetes prevalence was estimated by use of a Bayesian meta-regression modelling tool, DisMod-MR 2.1, to analyse 1527 location-years of data from the scientific literature, survey microdata, and insurance claims; type 2 diabetes estimates were computed by subtracting type 1 diabetes from total estimates. Mortality and prevalence estimates, along with standard life expectancy and disability weights, were used to calculate YLLs, YLDs, and DALYs. When appropriate, we extrapolated estimates to a hypothetical population with a standardised age structure to allow comparison in populations with different age structures. We used the comparative risk assessment framework to estimate the risk-attributable type 2 diabetes burden for 16 risk factors falling under risk categories including environmental and occupational factors, tobacco use, high alcohol use, high body-mass index (BMI), dietary factors, and low physical activity. Using a regression framework, we forecast type 1 and type 2 diabetes prevalence through 2050 with Socio-demographic Index (SDI) and high BMI as predictors, respectively. FINDINGS: In 2021, there were 529 million (95% uncertainty interval [UI] 500-564) people living with diabetes worldwide, and the global age-standardised total diabetes prevalence was 6·1% (5·8-6·5). At the super-region level, the highest age-standardised rates were observed in north Africa and the Middle East (9·3% [8·7-9·9]) and, at the regional level, in Oceania (12·3% [11·5-13·0]). Nationally, Qatar had the world's highest age-specific prevalence of diabetes, at 76·1% (73·1-79·5) in individuals aged 75-79 years. Total diabetes prevalence-especially among older adults-primarily reflects type 2 diabetes, which in 2021 accounted for 96·0% (95·1-96·8) of diabetes cases and 95·4% (94·9-95·9) of diabetes DALYs worldwide. In 2021, 52·2% (25·5-71·8) of global type 2 diabetes DALYs were attributable to high BMI. The contribution of high BMI to type 2 diabetes DALYs rose by 24·3% (18·5-30·4) worldwide between 1990 and 2021. By 2050, more than 1·31 billion (1·22-1·39) people are projected to have diabetes, with expected age-standardised total diabetes prevalence rates greater than 10% in two super-regions: 16·8% (16·1-17·6) in north Africa and the Middle East and 11·3% (10·8-11·9) in Latin America and Caribbean. By 2050, 89 (43·6%) of 204 countries and territories will have an age-standardised rate greater than 10%. INTERPRETATION: Diabetes remains a substantial public health issue. Type 2 diabetes, which makes up the bulk of diabetes cases, is largely preventable and, in some cases, potentially reversible if identified and managed early in the disease course. However, all evidence indicates that diabetes prevalence is increasing worldwide, primarily due to a rise in obesity caused by multiple factors. Preventing and controlling type 2 diabetes remains an ongoing challenge. It is essential to better understand disparities in risk factor profiles and diabetes burden across populations, to inform strategies to successfully control diabetes risk factors within the context of multiple and complex drivers. FUNDING: Bill & Melinda Gates Foundation.
Key Findings
1
Diabetes mortality was modelled with CODEm using 25,666 location-years of vital-registration and verbal-autopsy data.
2
It quantifies the proportions of type 1 and type 2 diabetes in 2021 and attributes selected components of type 2 diabetes burden to risk factors.
3
Prevalence estimates used DisMod-MR 2.1 and 1,527 location-years of literature, survey, and insurance-claims data; other forms, including gestational and monogenic diabetes, were not explicitly modelled.
4
The analysis projects diabetes prevalence through 2050 using the Global Burden of Disease Study 2021 analytical framework.
5
The study estimates diabetes prevalence, mortality, and DALYs from 1990 to 2021 across 204 countries and territories, by age and sex.
Research Object
Global, regional, and national burden of diabetes (1990–2021) with projections of diabetes prevalence to 2050
Research Subject
Temporal, geographic, demographic, and etiological patterns of diabetes prevalence, mortality, and DALY burden, including risk-attributable type 2 diabetes burden and projected prevalence
Publication Details
Publication Date
2023-06-23
Journal
Publisher
ISSN
Cited by
4702
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai7
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 20192020
Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin2002
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 20192020
Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories2018
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 20192020
Fertility, mortality, migration, and population scenarios for 195 countries and territories from 2017 to 2100: a forecasting analysis for the Global Burden of Disease Study2020
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 20192020
Cited by11
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 20212024
Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 20502024
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 20212024
Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 20212024
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 20212024
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review2024
Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine2023
Global Burden of the Key Components of Cardiovascular-Kidney-Metabolic Syndrome2025
Comparative diabetes mellitus burden trends across global, Chinese, US, and Indian populations using GBD 2021 database2025
The role of exercise intensity in the regulation of the gut microbiota and liver function in metabolic dysfunction–associated steatotic liver disease2026
Synthesis of Flaxseeds Aqueous Extract and Study Its Effectiveness on the Behavior Diabetic Mice2025